廣東宏大(002683.SZ):目前礦服板塊在手訂單逾300億元
格隆匯10月25日丨廣東宏大(002683.SZ)在投資者關係活動上表示,一是公司目前礦服板塊在手訂單逾300億元,每年新簽訂單穩中有增。服務的礦種以金屬礦為主,其次為煤炭、砂石骨料等。二是公司緊跟產業政策,今年新收購了宜興市陽生化工有限公司和青島盛世普天科技有限公司,公司在證產能提升至58萬噸,其中混裝產能33.8萬噸,佔比約58%。三是防務裝備板塊傳統訂單較上年同期有所增長,且公司在今年8月完成江蘇紅光剩餘46%股權的收購,防務裝備板塊業績有所提升。江蘇紅光主要產品黑索今是基礎含能材料,廣泛地應用於戰鬥部裝藥、推進劑、混合炸藥、雷管、起爆具、射孔彈製造、超硬材料加工等領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.